AbbVie — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.
BiotechHealthtechLongevityCambridge, US
Benjamin Wolozin(CSO & Co-founder)inDr. Glenn Larsen(Co-founder, President and CEO)Dr. Ben Wolozin(Co-Founder and Chief Scientific Officer)
Co-investorsPfizer Venture Investments
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentAnzu PartnersGrazia Equity GmbHHealthCapLongview Innovation+4 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








